Dana-Farber Cancer Institute | Strategic Alliance Partners

Mobocertinib may have limited intracranial activity in patients with EGFR exon 20 insertion–positive, non–small cell lung cancer with brain metastases at baseline, given the numerically lower response rate observed with the agent in this population.

The combination of lenalidomide (Revlimid), bortezomib, and dexamethasone (RVd) plus autologous stem cell transplant as initial therapy followed by lenalidomide maintenance demonstrated a significant improvement in progression-free survival vs RVd alone followed by lenalidomide maintenance in patients with newly diagnosed multiple myeloma.

Novel agents seek to improve and expand the efficacy of the current standard of care for patients with acute graft-vs-host disease, specifically those with high-risk disease.

The addition of sorafenib to conventional chemotherapy was safe and demonstrated evidence of improved outcomes in pediatric patients with FLT3-ITD–positive acute myeloid leukemia.

Paolo Tarantino, MD, discusses the importance of the phase 3 DESTINY-Breast04 trial in HER2-low breast cancer.

Dr Tarantino provides background on the categorization of HER2-low disease in breast cancer, issues with standardization and interpretation, historical management strategies, and ongoing research with agents including trastuzumab deruxtecan, trastuzumab duocarmazine, and disitamab vedotin.

In the context of checkpoint blockade in nasopharyngeal carcinoma, the results of the phase 3 RATIONALE-309 trial support earlier findings of the role immunotherapy may play for patients in the first line.

Ann H. Partridge, MD, MPH, discusses the utilization of GnRH agonists to preserve ovarian function in premenopausal patients with breast cancer.

Mark Awad, MD, PhD, discusses how the approval of nivolumab opens the door for the new regimen to become a backbone for future treatment strategies.

Dana-Farber Cancer Institute and the Lifespan Cancer Institute have agreed to renew their strategic alliance to advance cancer treatment and research. Dana-Farber and the Lifespan Cancer Institute signed an initial agreement in 2017.

Toni Choueiri, MD, discusses the next steps for the evaluation of pembrolizumab in the phase 3 KEYNOTE-564 trial (NCT03142334) in renal cell carcinoma.

The Gairdner Foundation has announced that Stuart H. Orkin, MD, is one of the 2022 Canada Gairdner Award laureates for seminal discoveries and contributions to biomedical science.

Dana-Farber Cancer Institute is launching a year-long celebration of its 75th anniversary to highlight its history and progress in cancer care and transformative cancer research.

Specialization in oncology research affords investigators the opportunity to dive into tumor biology and uncover unique approaches to care.

Ann S. LaCasce, MD, MMSc, discusses updates in lymphoma, myelofibrosis, and chronic lymphocytic leukemia.

Jacqueline S. Garcia, MD, discusses the results of the phase 2 REFINE trial in patients with myelofibrosis.

Inhye Ahn, MD, discusses the evolving treatment landscape of chronic lymphocytic leukemia, the advances made with BTK inhibitors and venetoclax-based regimens, novel combination regimens under exploration, and other research efforts that are underway.

Daniel J. DeAngelo, MD, PhD, discusses how the addition of uproleselan to various chemotherapy backbones is being investigated in ongoing clinical trials, plus the encouraging safety data tied to the lowered mucositis levels.

Encouraging response rates to a dual-targeted regimen in patients with recurrent or refractory malignant brain tumors with BRAF V600E mutations were reported in 2021, representing a new potential targeted therapy strategy against glioblastoma.

Sara M. Tolaney, MD, MPH, reviews practice-changing data sets throughout breast cancer and provides perspective on potential treatment approaches in the absence of definitive results.

Corey S. Cutler, MD, MPH, FRCPC, discusses the exploration of itolizumab in acute graft-versus-host disease.

Corey S. Cutler, MD, MPH, FRCPC, notes the clinical benefit observed with itolizumab in EQUATE and the observations that informed the design of the phase 3 EQUATOR trial.

Data presented at the ASH Annual Meeting and Exposition underscored the growing focus on improving screening, advancing methods of detection, and improving our understanding of the genomic, genetic, and epigenetic factors that govern progression and therapeutic resistance in multiple myeloma.

The addition of itolizumab to standard-of-care corticosteroids vs placebo will be evaluated in patients with acute graft-versus-host disease, as part of the phase 3 EQUATOR trial.

John Koreth, MBBS, DPhil, discusses the key objectives of the phase 3 EQUATOR trial in acute graft-versus-host disease.

Daniel J. DeAngelo, MD, PhD, discusses the exploration of uproleselan plus chemotherapy in relapsed/refractory acute myeloid leukemia.

Paul G. Richardson, MD, started his journey in medicine delivering tea and biscuits to patients and ended up making seminal advances in myeloma care.

The combination of abemaciclib and letrozole produced encouraging responses with an acceptable toxicity profile in patients with estrogen receptor–positive, recurrent or metastatic endometrial cancer with endometrioid histology, according to data from a phase 2 trial.

Toni K. Choueiri, MD, discusses follow-up data from the pivotal phase 3 KEYNOTE-564 examining adjuvant pembrolizumab in patients with clear cell RCC and additional areas that are ripe for further research.

Ursula A. Matulonis, MD, discusses the results of the phase 3 SORAYA trial in platinum-resistant ovarian cancer.